

2 FINANCIAL HIGHLIGHTS

2.1 Principal Financial Data and Indicators

		For the six months ended June 30,	
		2020	2019
		(RMB'000)	(USD'000)
		(Unaudited)	(Unaudited)
Operating income		465,150	378,910
Operating expenses		39,404	52,661
Operating profit		(10,503)	(7,120)
Financial income		28,901	45,541
Financial expenses		36,410	52,064
Financial profit		(7,509)	(6,523)
Profit before income tax			
Income tax			
Profit after income tax			
As at		As at	
June 30,		December 31,	
2020		2019	
(RMB'000)		(USD'000)	
(Unaudited)		(Unaudited)	
Assets		2,274,908	2,117,352
Liabilities		960,485	855,843
Equity		1,314,423	1,261,509
Profit before income tax		1,186,459	1,164,484
Income tax		127,964	97,025

4.1 Financial Review

1. 下列各句，没有语病的一项是（ ）
 A. 在 2008 年 5 月 12 日汶川大地震发生后，全国人民纷纷捐款捐物，为灾区同胞献爱心。
 B. 通过这次活动，使我们增长了知识，开阔了眼界。
 C. 为了防止这类事故不再发生，我们必须采取有效措施。
 D. 为了防止非典疫情不再蔓延，政府决定实行严格的防控措施。

2. 下列各句，标点符号使用正确的一项是（ ）
 A. 他问：“你叫什么名字？”
 B. 他问：“你叫什么名字？”
 C. 他问：“你叫什么名字？”
 D. 他问：“你叫什么名字？”

4

For the six months ended June 30, 2020 (Unaudited) 2019 (Unaudited)

	2020 (Unaudited)	2019 (Unaudited)
Inpatients		
Number of inpatient admissions	6,853	5,593
Revenue from inpatient services (RMB'000)	1,240,393	1,012,333
Percentage of total revenue (%)	83.1	84.9
Number of inpatient bed-days	1,030,392	859,061
Average inpatient spending per bed-day (RMB)	324,990	251,945
Number of inpatient admissions (B)	315	293
Average inpatient spending per admission (RMB'000)	53,841	50,926
Average inpatient spending per admission (B)	52	59
Total inpatient revenue (RMB'000)	378,831	302,871
Total average inpatient spending per bed-day (RMB)	368	353
Outpatients		
Number of outpatient visits	125,852	105,986
Revenue from outpatient services (RMB'000)	12,761	11,635
Average outpatient spending per visit (RMB)	101	110
Number of outpatient visits (B)	47,294	45,704
Average outpatient spending per visit (RMB'000)	376	431
Total outpatient revenue (RMB'000)	60,055	57,339
Total average outpatient spending per visit (RMB)	477	541
Total treatment and general healthcare services revenue (RMB'000)	337,751	263,580
Total pharmaceutical sales revenue (RMB'000)	101,135	96,630

Decreased by 25.1% (2019: 19.9%) to RMB378.8 million, or 4.2% of revenue (2019: 86.3% (2019: 84.1%)).

Decreased by 4.7% (2019: 18.7%) to RMB60.1 million, or 13.7% of revenue (2019: 15.9%).

Decreased by 28.1% (2019: 77.0%) to RMB23.0 million, or 4.7% of revenue (2019: 73.2%); decreased by 23.0% (2019: 26.8%) to RMB14.2 million, or 3.0% of revenue (2019: 16.8%), decreased by 78.8% (2019: 79.7%) to RMB0.5 million, or 0.1% of revenue (2019: 0.1%).

Cost of revenue of owned hospitals decreased by 1.2% (2019: 1.2%) to RMB112,156 thousand, or 101,813 thousand (2019: 91,091 thousand).

	For the six months ended June 30,	
	2020 (RMB'000) (Unaudited)	2019 (RMB'000) (Audited)
Cost of revenue of owned hospitals	112,156	101,813
Cost of revenue of leased hospitals	110,048	91,091
Cost of revenue of joint venture hospitals	15,297	14,119
Cost of revenue of hospitals under construction	37,019	30,236
Cost of revenue of hospitals under management	18,390	16,577
Cost of revenue of hospitals under cooperation	11,647	7,807
	<u>18,906</u>	<u>18,290</u>
Cost of revenue of owned hospitals	<u>323,463</u>	<u>279,933</u>

D, 2019, B323.5, 15.6%, 28.1%, 2019; () ; () .

F, 34.7% (30, 2019: 36.4%). 34.0% (30, 2019: 32.5%). 16.2% (30, 2019: 15.8%).

2019, D, B19.1, B11.3 (30, 2019: B12.8); B5.8 (30, 2019:).

2019, D, B7.1 (30, 2019: B3.4 B3.9).

4.1.2 Gross Profit and Gross Profit Margin

During the six months ended June 30, 2020, gross profit was \$128.3 million, or 39.4% of net sales, compared to \$115.4 million, or 43.8% of net sales, for the six months ended June 30, 2019. The decrease in gross profit was primarily due to the impact of the COVID-19 pandemic on our operations.	
--	--

	For the six months ended June 30,	
	2020 (Unaudited)	2019 (Audited)
Gross profit	29.7%	25.1%
Operating expenses	14.9%	14.5%
Operating income	26.3%	22.3%
Operating income as a percentage of net sales	47.1%	62.8%
Consolidated gross profit margin	27.6%	24.3%

During the six months ended June 30, 2020, gross profit margin was 27.6% (compared to 24.3% for the six months ended June 30, 2019), an increase of 3.3 percentage points. The increase in gross profit margin was primarily due to the impact of the COVID-19 pandemic on our operations.

4.1.3 Tax and Surcharge

During the six months ended June 30, 2020, tax and surcharge expense was \$2.0 million, or 0.8% of net sales, compared to \$0.8 million, or 0.3% of net sales, for the six months ended June 30, 2019. The increase in tax and surcharge expense was primarily due to the impact of the COVID-19 pandemic on our operations.

4.1.4 Selling Expenses

During the six months ended June 30, 2020, selling expenses were \$4.5 million, or 1.8% of net sales, compared to \$3.7 million, or 1.5% of net sales, for the six months ended June 30, 2019. The increase in selling expenses was primarily due to the impact of the COVID-19 pandemic on our operations.

4.1.5 Administrative Expenses

During the six months ended June 30, 2020, administrative expenses decreased by RMB54.6 thousand (3.3%) from RMB164.5 thousand in 2019, mainly due to the decrease in depreciation and amortization expenses of RMB20.0 thousand (12.4%) and the decrease in employee benefits of RMB14.5 thousand (8.8%).

	For the six months ended June 30,	
	2020 (RMB'000) (Unaudited)	2019 (RMB'000)
Employee benefits	35,136	33,962
Depreciation and amortization	5,970	5,709
Consulting fees	2,406	3,976
Transportation	1,468	2,188
	<u>9,659</u>	<u>7,055</u>
Total administrative expenses	<u>54,639</u>	<u>52,890</u>

During the six months ended June 30, 2020, administrative expenses decreased by RMB54.6 thousand (3.3%) from RMB164.5 thousand in 2019, mainly due to the decrease in depreciation and amortization expenses of RMB20.0 thousand (12.4%) and the decrease in employee benefits of RMB14.5 thousand (8.8%).

4.1.6 Research and Development Expenses

During the six months ended June 30, 2020, research and development expenses decreased by RMB2.6 million (14.5%) from RMB18.0 million in 2019, mainly due to the decrease in depreciation and amortization expenses of RMB0.6 million (3.3%) and the decrease in employee benefits of RMB1.4 million (7.7%).

4.1.7 Finance Expenses – Net

For the six months ended June 30, 2020, the Company's net finance expenses were RMB125,000 (2019: RMB759,000). The Company's net finance expenses for the six months ended June 30, 2020, were RMB125,000 (2019: RMB759,000).

	For the six months ended June 30,	
	2020	2019
	(RMB'000)	(RMB'000)
	(Unaudited)	(Unaudited)
Interest income	2,454	1,925
Finance expense/(income)	125	(759)
Net finance expense	(9,165)	(3,520)
Net finance expense	(4,921)	(5,706)
Net finance expense	125	

The amount of net finance expense for the six months ended June 30, 2020, was RMB125,000 (2019: RMB759,000).

Decreased by B1.0, or 0.1%, from 2019, and decreased by B0.9, or 0.1%, from 2018.

4.1.9 Credit Impairment Losses

Decreased by B16.1, or 3.5%, from 2019 (2019: B10.7), and decreased by B30.3, or 8.6%, from 2018 (2018: B21.4). As a percentage of average loans, credit impairment losses decreased from 7.1% in 2019 to 6.2% in 2020.

4.1.10 Non-Operating Income (Expenses) and Other Gains

Increased by B1.0, or 0.1%, from 2019, and decreased by B0.9, or 0.1%, from 2018.

4.1.11 Income Tax Expense

D, 30, 2019: B7.1, B10.5 (47.5%
 2019. F
 30, 2019, 26.7% 13.5%,
 B
 2019,
 ,

4.2 Financial Position

4.2.1 Inventory

A 30, 2020, B33.9 (D
 31, 2019: B23.6), : ()
 B31.3 (D 31, 2019: B21.0);
 () B2.6 (D 31, 2019:
 B2.6), 2701, 2806, 2807 2808
 k B, C
 C
 :

C 2701, 2806, 2807
 2808 k B,
 C E, C
 C

A
 C, C E, C,
 C

75%

(A) () 19.3

(A) () 325.73

C,

C

C 30, 2017

4.2.2 Accounts Receivables

A _____, 30, 2020, _____ B352.6
 (_____ D _____ 31, 2019: _____ B310.5 _____), _____
 _____ 14.5% _____ D _____ 31, 2019, _____
 _____ 2019, _____
 D _____ 133 _____ (_____ 30, 2019: 146 _____).

4.2.3 Other Receivables and Prepayments

A _____, 30, 2020, _____ B88.4
 (_____ D _____ 31, 2019: _____ B68.7 _____).

4.2.4 Investment Properties

A _____, 30, 2020, _____ B107.1
 (_____ D _____ 31, 2019: _____ B110.9 _____), _____ k
 B, _____ C _____ E, _____ C _____ (_____ 302, _____ 303
 304) _____ k B, _____ C _____ E, _____
 _____ C _____ (2/F _____ 11/F) _____ D, _____
 _____ :
 _____ k B, _____ C
 _____ E, _____ C
 (_____ 302, _____ 303 _____ 304)
 A _____
 E, _____ C, _____ C
 _____ C, _____ C
 _____ 75%
 _____ (A _____) (_____) 1,959.41
 _____ (A _____) (_____) 6,766,36

	29, 2043,
	k. B, C
	E, C
	(2/F, 11/F)
A	E, C, C
	C, C
	75%
(A,) (,)	6,602.26
(A,) (,)	11,850.34
	C,
	29, 2043,

4.2.5 Other Non-current Financial Assets

A, 30, 2020, B51.3 (D 31, 2019: B51.3). D,

4.2.6 Right-of-use Assets

A, 30, 2020, B253.4 (D 31, 2019: B235.3), C.

4.2.7 Accounts Payables

A, 30, 2020, B63.6 (D 31, 2019: B75.6).

4.2.8 Contract Liability

As at June 30, 2020, the balance of contract liability was RMB10.8 million (December 31, 2019: RMB8.6 million).

4.2.9 Other Payables

As at June 30, 2020, the balance of other payables was RMB93.5 million (December 31, 2019: RMB133.3 million).

4.3 Liquidity and Capital Resources

The following table summarizes the cash flows from operating, investing and financing activities for the six months ended June 30, 2020 and 2019:

		For the six months ended June 30,	
		2020	2019
		(RMB'000)	(RMB'000)
		(Unaudited)	(Unaudited)
Cash generated from operating activities		17,799	4,157
Net cash generated from investing activities		(76,436)	(75,880)
Net cash generated from financing activities		94,945	(25,941)
Net change in cash and cash equivalents		36,424	(98,423)

4.3.1 Net Cash Generated from Operating Activities

During the six months ended June 30, 2020, net cash generated from operating activities was RMB17.8 million, compared with RMB28.9 million for the same period in 2019. The increase was mainly due to the following factors: (i) an increase in net income of RMB16.1 million; (ii) an increase in net cash generated from operating activities of RMB90.9 million; and (iii) an increase in net cash generated from operating activities of RMB14.5 million.

4.3.2 Net Cash Used in Investing Activities

During the six months ended June 30, 2020, net cash used in investing activities was RMB76.4 million, compared with RMB67.1 million for the same period in 2019. The increase was mainly due to the following factors: (i) an increase in net cash used in investing activities of RMB76.4 million; and (ii) an increase in net cash used in investing activities of RMB67.1 million.

4.3.3 Net Cash Generated from Financing Activities

Decrease in cash and cash equivalents	B94.9	Decrease in cash and cash equivalents	B163.5
Net cash generated from financing activities	B39.1	Net cash generated from financing activities	B163.5

4.3.4 Significant Investment, Acquisition and Disposal

Investment in subsidiaries	B1,000.0	Investment in subsidiaries	B1,000.0
Disposal of subsidiaries	B1,000.0	Disposal of subsidiaries	B1,000.0
Net cash generated from financing activities	B39.1	Net cash generated from financing activities	B163.5

4.4 Indebtedness

4.4.1 Bank Borrowings

Bank borrowings at 30, 2020, (B364.5)	B473.5	Bank borrowings at 31, 2019: (B201.0)	B310.0
Net cash generated from financing activities	B39.1	Net cash generated from financing activities	B163.5

4.4.2 Contingent Liability

Contingent liability at 30, 2020, (B1,000.0)	B1,000.0	Contingent liability at 31, 2019: (B1,000.0)	B1,000.0
Net cash generated from financing activities	B39.1	Net cash generated from financing activities	B163.5

4.4.3 Asset Pledge

Asset pledge at 30, 2020, (B1,000.0)	B1,000.0	Asset pledge at 31, 2019: (B1,000.0)	B1,000.0
Net cash generated from financing activities	B39.1	Net cash generated from financing activities	B163.5

4.4.4 Lease Liabilities

Lease liabilities at 30, 2020, (B186.0)	B24.2	Lease liabilities at 31, 2019: (B186.0)	B186.0
Net cash generated from financing activities	B39.1	Net cash generated from financing activities	B163.5

4.4.5 Financial Instruments

Financial instruments at 30, 2020, (B1,000.0)	B1,000.0	Financial instruments at 31, 2019: (B1,000.0)	B1,000.0
Net cash generated from financing activities	B39.1	Net cash generated from financing activities	B163.5

4.4.6 Exposure to Fluctuation in Exchange Rates

As at 30, 2020, the Company's exposure to foreign exchange risk is primarily in the form of receivables and payables denominated in US dollars. The Company's policy is to maintain a net zero position in respect of foreign exchange risk. The Company's policy is to enter into forward contracts to hedge its foreign exchange risk. The Company's policy is to enter into forward contracts to hedge its foreign exchange risk. The Company's policy is to enter into forward contracts to hedge its foreign exchange risk.

4.4.7 Gearing Ratio

As at 30, 2020, the Company's gearing ratio is 42.2% (31, 2019: 40.4%).

4.4.8 Employees and Remuneration Policy

As at 30, 2020, the Company has 3,136 employees (31, 2019: 2,845). The Company's remuneration policy is to provide competitive remuneration to its employees. The Company's remuneration policy is to provide competitive remuneration to its employees. The Company's remuneration policy is to provide competitive remuneration to its employees.

The Company's remuneration policy is to provide competitive remuneration to its employees. The Company's remuneration policy is to provide competitive remuneration to its employees. The Company's remuneration policy is to provide competitive remuneration to its employees.

As at 30, 2020, the Company's remuneration policy is to provide competitive remuneration to its employees. The Company's remuneration policy is to provide competitive remuneration to its employees. The Company's remuneration policy is to provide competitive remuneration to its employees.

A 15
 B C A 26, 2019, B
 C 37
 273,161 A 14
 23
 180,516 0.2391%
 C
 (B10.47).

Category of personnel	Number of persons granted (person)	Number of Shares granted (Share)	Number of grant representing total issued share capital of the Company
C	17	142,311	0.1885%
B	6	38,204	0.0506%
	23	180,516	0.2391%

C
 (溫州箴言康寧投資管理合夥企業(有限合夥))
 48
 k 48

5 PURCHASE, SALE AND REDEMPTION OF LISTED SECURITIES

During the reporting period, the Company repurchased 899,700 shares of its ordinary shares under the share repurchase plan, with a total consideration of RMB15,888,990. Details are as follows:

Repurchase period	Total number of H Shares repurchased	Price paid per share		Total consideration
		Highest (RMB \$)	Lowest (RMB \$)	
January 2020	35,000	17.90	17.80	624,200
April 2020	715,200	18.56	17.70	12,993,510
May 2020	9,400	16.00	15.80	148,540
June 2020	140,100	15.30	14.70	2,122,740
	899,700			15,888,990

The share repurchase plan was approved by the Board of Directors on March 13, 2020.

There were no share repurchases, share sales or share redemptions of the Company's ordinary shares during the reporting period.

6 EVENTS AFTER THE REPORTING PERIOD

From June 30, 2020 to the date of approval of this financial statement, there were no events after the reporting period that require disclosure.

7 REVIEW OF INTERIM RESULTS

T. A. C.  30, 2020,  ,

Figure 1: A diagram illustrating the structure of the $\mathcal{H}_\infty$ norm. The diagram shows a system with input u and output y . The system is represented by a block labeled G . The input u is split into two paths: one path goes through a block labeled A and then a block labeled C , and the other path goes through a block labeled D . The output y is the sum of the outputs of the A and C blocks. The $\mathcal{H}_\infty$ norm is defined as the maximum singular value of the transfer function G .

8 INTERIM DIVIDEND

30, 2020 (<https://www.fishbase.org/species/0300>), 30, 2019: (<https://www.fishbase.org/species/0300>).

9 COMPLIANCE WITH CG CODE

C


10 ACCOUNTING STANDARDS

2017, (C 622/17) (Companies Ordinance).

11 FINANCIAL REPORT

11.1 Accounting Policies

B, E, B, F, C (“Ministry of Finance”) F, 15, 2006.

32 

2019. 7

1. *What is the purpose of the study?*

2016.

11.2 Interim Financial Statement

$\text{A} = \text{B} + \text{C}$
 $\text{A} = \text{B} + \text{C}$

11.2.1 Interim Consolidated Income Statement

(A = B + C)

		For the six months ended June 30,	
		2020 (Unaudited)	2019 (Unaudited)
1. Revenue		465,150,452	378,910,291
Cost of sales		(336,864,754)	(286,882,183)
Gross profit		(1,999,246)	(831,972)
Operating expenses		(3,697,157)	(4,476,806)
Operating income		(54,639,015)	(52,890,346)
Finance income		(2,637,407)	(2,304,024)
Finance expense		(11,846,196)	(10,198,874)
Income before income tax		(14,086,629)	(11,068,131)
Income tax expense		2,454,371	1,925,426
Income before non-recurring items		5,443,616	6,567,461
Non-recurring items		(923,557)	23,549,073
Income before income tax		(1,019,927)	(2,525,317)
Income tax expense		(16,112,650)	(10,730,916)
Income before non-recurring items		—	(18,587)

11.2.2 Interim Consolidated Statement of Financial Position

(As at June 30, 2020 and December 31, 2019)

ASSETS	June 30, 2020 (Unaudited)	December 31, 2019 (Audited)
Current assets		
Cash and cash equivalents	216,156,858	176,030,550
Financial assets at fair value through profit or loss	–	30,000,000
Accounts receivable	352,645,140	310,520,612
Prepaid expenses and other receivables	76,843,282	63,317,366
Assets held for sale	11,516,259	5,366,020
Other non-current assets	33,858,107	23,568,236
Current tax receivable	–	12,688,704
Total current assets	691,019,646	621,491,488
Non-current assets		
Financial assets at fair value through profit or loss	51,281,869	51,281,869
Other non-current assets	94,068,266	89,943,193

LIABILITIES AND SHAREHOLDERS' EQUITY	June 30, 2020 (Unaudited)	December 31, 2019 (Audited)
Current liabilities		
Accounts payable and accrued liabilities	332,500,000	250,000,000
Short-term debt	576,686	—
Accounts receivable	63,565,539	75,554,960
Contract liabilities	10,772,528	8,562,126
Employee compensation and benefits	23,923,352	36,063,277
Deferred revenue	44,736,621	33,430,060
Income taxes payable	93,516,092	133,348,712
Contractual obligations	66,053,557	79,741,922
Total current liabilities	635,644,375	616,701,057
Non-current liabilities		
Long-term debt	100,500,000	20,000,000
Deferred tax liabilities	186,013,332	183,808,151
Other non-current liabilities	580,000	2,260,000
Long-term contract liabilities	2,000,000	2,000,000
Deferred compensation	9,797,371	9,949,267
Deferred interest	25,949,596	21,124,118
Total non-current liabilities	324,840,299	239,141,536
Total liabilities	960,484,674	855,842,593
Shareholders' equity		
Common stock	75,500,000	75,500,000
Capital in excess of par value	826,376,743	824,715,445
Accumulated deficit	(37,817,508)	(21,721,144)
Other equity	33,189,321	33,189,321
Shareholders' equity	289,210,662	252,800,715
Total equity attributable to shareholders of the parent company	1,186,459,218	1,164,484,337
Non-controlling interest	127,964,021	97,024,925
Total shareholders' equity	1,314,423,239	1,261,509,262
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	2,274,907,913	2,117,351,855

11.2.3 Interim Consolidated Statements of Cash Flow

(A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z) (AA) (AB) (AC) (AD) (AE) (AF) (AG) (AH) (AI) (AJ) (AK) (AL) (AM) (AN) (AO) (AP) (AQ) (AR) (AS) (AT) (AU) (AV) (AW) (AX) (AY) (AZ) (BA) (BB) (BC) (BD) (BE) (BF) (BG) (BH) (BI) (BJ) (BK) (BL) (BM) (BN) (BO) (BP) (BQ) (BR) (BS) (BT) (BU) (BV) (BW) (BX) (BY) (BZ) (CA) (CB) (CC) (CD) (CE) (CF) (CG) (CH) (CI) (CJ) (CK) (CL) (CM) (CN) (CO) (CP) (CQ) (CR) (CS) (CT) (CU) (CV) (CW) (CX) (CY) (CZ) (DA) (DB) (DC) (DD) (DE) (DF) (DG) (DH) (DI) (DJ) (DK) (DL) (DM) (DN) (DO) (DP) (DQ) (DR) (DS) (DT) (DU) (DV) (DW) (DX) (DY) (DZ) (EA) (EB) (EC) (ED) (EE) (EF) (EG) (EH) (EI) (EJ) (EK) (EL) (EM) (EN) (EO) (EP) (EQ) (ER) (ES) (ET) (EU) (EV) (EW) (EX) (EY) (EZ) (FA) (FB) (FC) (FD) (FE) (FF) (FG) (FH) (FI) (FJ) (FK) (FL) (FM) (FN) (FO) (FP) (FQ) (FR) (FS) (FT) (FU) (FV) (FW) (FX) (FY) (FZ) (GA) (GB) (GC) (GD) (GE) (GF) (GG) (GH) (GI) (GJ) (GK) (GL) (GM) (GN) (GO) (GP) (GQ) (GR) (GS) (GT) (GU) (GV) (GW) (GX) (GY) (GZ) (HA) (HB) (HC) (HD) (HE) (HF) (HG) (HH) (HI) (HJ) (HK) (HL) (HM) (HN) (HO) (HP) (HQ) (HR) (HS) (HT) (HU) (HV) (HW) (HX) (HY) (HZ) (IA) (IB) (IC) (ID) (IE) (IF) (IG) (IH) (II) (IJ) (IK) (IL) (IM) (IN) (IO) (IP) (IQ) (IR) (IS) (IT) (IU) (IV) (IW) (IX) (IY) (IZ) (JA) (JB) (JC) (JD) (JE) (JF) (JG) (JH) (JI) (JJ) (JK) (JL) (JM) (JN) (JO) (JP) (JQ) (JR) (JS) (JT) (JU) (JV) (JW) (JX) (JY) (JZ) (KA) (KB) (KC) (KD) (KE) (KF) (KG) (KH) (KI) (KJ) (KK) (KL) (KM) (KN) (KO) (KP) (KQ) (KR) (KS) (KT) (KU) (KV) (KW) (KX) (KY) (KZ) (LA) (LB) (LC) (LD) (LE) (LF) (LG) (LH) (LI) (LJ) (LK) (LL) (LM) (LN) (LO) (LP) (LQ) (LR) (LS) (LT) (LU) (LV) (LW) (LX) (LY) (LZ) (MA) (MB) (MC) (MD) (ME) (MF) (MG) (MH) (MI) (MJ) (MK) (ML) (MM) (MN) (MO) (MP) (MQ) (MR) (MS) (MT) (MU) (MV) (MW) (MX) (MY) (MZ) (NA) (NB) (NC) (ND) (NE) (NF) (NG) (NH) (NI) (NJ) (NK) (NL) (NM) (NN) (NO) (NP) (NQ) (NR) (NS) (NT) (NU) (NV) (NW) (NX) (NY) (NZ) (OA) (OB) (OC) (OD) (OE) (OF) (OG) (OH) (OI) (OJ) (OK) (OL) (OM) (ON) (OO) (OP) (OQ) (OR) (OS) (OT) (OU) (OV) (OW) (OX) (OY) (OZ) (PA) (PB) (PC) (PD) (PE) (PF) (PG) (PH) (PI) (PJ) (PK) (PL) (PM) (PN) (PO) (PP) (PQ) (PR) (PS) (PT) (PU) (PV) (PW) (PX) (PY) (PZ) (QA) (QB) (QC) (QD) (QE) (QF) (QG) (QH) (QI) (QJ) (QK) (QL) (QM) (QN) (QO) (QP) (QQ) (QR) (QS) (QT) (QU) (QV) (QW) (QX) (QY) (QZ) (RA) (RB) (RC) (RD) (RE) (RF) (RG) (RH) (RI) (RJ) (RK) (RL) (RM) (RN) (RO) (RP) (RQ) (RR) (RS) (RT) (RU) (RV) (RW) (RX) (RY) (RZ) (SA) (SB) (SC) (SD) (SE) (SF) (SG) (SH) (SI) (SJ) (SK) (SL) (SM) (SN) (SO) (SP) (SQ) (SR) (SS) (ST) (SU) (SV) (SW) (SX) (SY) (SZ) (TA) (TB) (TC) (TD) (TE) (TF) (TG) (TH) (TI) (TJ) (TK) (TL) (TM) (TN) (TO) (TP) (TQ) (TR) (TS) (TT) (TU) (TV) (TW) (TX) (TY) (TZ) (UA) (UB) (UC) (UD) (UE) (UF) (UG) (UH) (UI) (UJ) (UK) (UL) (UM) (UN) (UO) (UP) (UQ) (UR) (US) (UT) (UU) (UV) (UW) (UX) (UY) (UZ) (VA) (VB) (VC) (VD) (VE) (VF) (VG) (VH) (VI) (VJ) (VK) (VL) (VM) (VN) (VO) (VP) (VQ) (VR) (VS) (VT) (VU) (VV) (VW) (VX) (VY) (VZ) (WA) (WB) (WC) (WD) (WE) (WF) (WG) (WH) (WI) (WJ) (WK) (WL) (WM) (WN) (WO) (WP) (WQ) (WR) (WS) (WT) (WU) (WV) (WW) (WX) (WY) (WZ) (XA) (XB) (XC) (XD) (XE) (XF) (XG) (XH) (XI) (XJ) (XK) (XL) (XM) (XN) (XO) (XP) (XQ) (XR) (XS) (XT) (XU) (XV) (XW) (XZ) (YA) (YB) (YC) (YD) (YE) (YF) (YG) (YH) (YI) (YJ) (YK) (YL) (YM) (YN) (YO) (YP) (YQ) (YR) (YS) (YT) (YU) (YV) (YW) (YZ) (ZA) (ZB) (ZC) (ZD) (ZE) (ZF) (ZG) (ZH) (ZI) (ZJ) (ZK) (ZL) (ZM) (ZN) (ZO) (ZP) (ZQ) (ZR) (ZS) (ZT) (ZU) (ZV) (ZW) (ZX) (ZY) (ZZ)

	For the six months ended June 30,	
	2020 (Unaudited)	2019 (Unaudited)
1. Cash flows from operating activities		
Cash received from customers	411,405,749	337,771,543
Cash received from other sources	8,311,056	7,188,089
Sub-total of cash inflows	419,716,805	344,959,632
Cash paid for operating expenses	(174,912,876)	(153,687,796)
Cash paid for interest	(162,022,960)	(137,201,128)
Cash paid for income taxes	(14,474,391)	(20,832,826)
Cash paid for other operating activities	(50,507,831)	(29,080,692)
Sub-total of cash outflows	(401,918,058)	(340,802,442)
Net cash flows from operating activities	17,798,747	4,157,190
2. Cash flows from investing activities		
Cash received from the sale of property, plant and equipment	30,010,000	447,095
Cash received from the sale of investments	96,370	—
Cash received from the sale of other assets	3,870,905	—
Cash paid for the acquisition of property, plant and equipment	—	1,833,758
Cash paid for the acquisition of investments	—	2,555,426
Sub-total of cash inflows	33,977,275	4,836,279
Cash paid for the acquisition of property, plant and equipment	(67,075,009)	(63,099,075)
Cash paid for the acquisition of investments	(15,145,000)	(13,020,000)
Cash paid for the acquisition of other assets	(25,593,510)	(1,246,349)
Cash paid for other investing activities	(2,600,000)	(3,351,048)
Sub-total of cash outflows	(110,413,519)	(80,716,472)
Net cash flows used in investing activities	(76,436,244)	(75,880,193)

	For the six months ended June 30, 2020	2019
	<i>(Unaudited)</i>	<i>(Unaudited)</i>
3. Cash flows from financing activities		
Cash received from issuance of shares	23,361,500	4,245,000
Cash received from bank loans:		
Long-term bank loans	21,771,500	4,245,000
Cash received from other financial institutions	367,285,789	170,000,000
Cash paid for acquisition of subsidiaries	—	—
Sub-total of cash inflows	390,647,289	174,245,000
Cash paid for acquisition of subsidiaries	(201,900,000)	(146,000,000)
Cash paid for purchase of intangible assets	(8,241,036)	(6,647,896)
Cash paid for purchase of property, plant and equipment	(85,561,157)	(47,538,263)
Sub-total of cash outflows	(295,702,193)	(200,186,159)
Net cash flows generated from/(used in) financing activities	94,945,096	(25,941,159)
4. Effect of foreign exchange rate changes on cash and cash equivalents	116,743	(758,597)
5. Net increase/(decrease) in cash and cash equivalents	36,424,342	(98,422,759)

11.2.4 Interim Consolidated Statement of Changes in Shareholders' Equity

(Amounts in millions of U.S. dollars)

	Equity attributable to shareholders of the parent company					Non-	Total
	Share	Capital	Less:	Surplus	Retained	controlling	shareholders'
	capital	surplus	Treasury	reserve	earnings	interests	equity
			stock				
Balance at January 1, 2020	75,500,000	824,715,445	(21,721,144)	33,189,321	252,800,715	97,024,925	1,261,509,262
Net income	-	-	-	-	36,409,947	(7,508,712)	28,901,235
Other comprehensive income	-	-	-	-	-	21,771,500	21,771,500
Dividends paid	-	3,914,851	(1,590,000)	-	-	-	2,324,851
Share-based compensation	-	(2,253,553)	-	-	-	(1,709,223)	(3,962,776)
Repurchase of common stock	-	-	(14,506,364)	-	-	-	(14,506,364)
Balance at June 30, 2020 (Unaudited)	75,500,000	826,376,743	(37,817,508)	33,189,321	289,210,662	127,964,021	1,314,423,239

Equity attributable to shareholders of the parent company

Balance at January 1, 2020

Share
capital

Capital

Td (75,500,000)Tj 7.206 0 Td (826,376,743)Tj 7.87370 T9,88637,

11.3 Notes to the Interim Financial Statement prepared in accordance with the China Accounting Standard for Business Enterprises

11.3.1 Accounts Receivable

(Amount in thousands of RMB)

	June 30, 2020 (Unaudited)	December 31, 2019 (Audited)
Accounts receivable	6,750,000	8,250,000
Allowance for doubtful accounts	384,779,056	330,174,215
Accounts receivable, net	391,529,056	338,424,215
Less: Accounts receivable transferred to the special purpose vehicle	(38,883,916)	(27,903,603)
Accounts receivable, net of transferred	<u>352,645,140</u>	<u>310,520,612</u>

The carrying amount of accounts receivable as of June 30, 2020 and December 31, 2019 is disclosed in Note 11.3.2.

	June 30, 2020 (Unaudited)	December 31, 2019 (Audited)
Accounts receivable by nature	307,256,118	266,932,953
Accounts receivable by nature	54,328,309	57,988,407
Accounts receivable by nature	24,130,088	13,089,001
Accounts receivable by nature	5,814,541	413,854
Accounts receivable, net of transferred	<u>391,529,056</u>	<u>338,424,215</u>

Accounts receivable are classified into three categories: (1) Accounts receivable with specific risk, (2) Accounts receivable with general risk, and (3) Accounts receivable with no risk.

11.3.2 Accounts Payable

(A ☐ B ☒)

For the six months ended June 30, 2020 D 31, 2019

	June 30, 2020 (Unaudited)	D 31, 2019 (A)
☒ 3	54,973,453	65,881,555
☒ 6	5,224,098	7,479,995
6 1	2,277,029	1,381,101
1 2	578,371	506,880
2 3	276,874	94,816
3	235,714	210,613
	63,565,539	75,554,960

11.3.3 Revenue and Cost of Sales

(A ☐ B ☒)

	For the six months ended June 30,	
	2020 (Unaudited)	2019 (A)
Revenue	438,885,748	360,209,402
Cost of sales	26,264,704	18,700,889
	465,150,452	378,910,291
C	323,463,045	279,933,288
C	13,401,709	6,948,895
	336,864,754	286,882,183

$$(A \quad , \quad \begin{array}{c} \text{A} \\ \text{B} \end{array} \quad , \quad \begin{array}{c} \text{A} \\ \text{B} \end{array} \quad)$$
31

11.3.4 Earnings Per Share

(A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z) (AA) (AB) (AC) (AD) (AE) (AF) (AG) (AH) (AI) (AJ) (AK) (AL) (AM) (AN) (AO) (AP) (AQ) (AR) (AS) (AT) (AU) (AV) (AW) (AX) (AY) (AZ) (BA) (BB) (BC) (BD) (BE) (BF) (BG) (BH) (BI) (BJ) (BK) (BL) (BM) (BN) (BO) (BP) (BQ) (BR) (BS) (BT) (BU) (BV) (BW) (BX) (BY) (BZ) (CA) (CB) (CC) (CD) (CE) (CF) (CG) (CH) (CI) (CJ) (CK) (CL) (CM) (CN) (CO) (CP) (CQ) (CR) (CS) (CT) (CU) (CV) (CW) (CX) (CY) (CZ) (DA) (DB) (DC) (DD) (DE) (DF) (DG) (DH) (DI) (DJ) (DK) (DL) (DM) (DN) (DO) (DP) (DQ) (DR) (DS) (DT) (DU) (DV) (DW) (DX) (DY) (DZ) (EA) (EB) (EC) (ED) (EE) (EF) (EG) (EH) (EI) (EJ) (EK) (EL) (EM) (EN) (EO) (EP) (EQ) (ER) (ES) (ET) (EU) (EV) (EW) (EX) (EY) (EZ) (FA) (FB) (FC) (FD) (FE) (FF) (FG) (FH) (FI) (FJ) (FK) (FL) (FM) (FN) (FO) (FP) (FQ) (FR) (FS) (FT) (FU) (FV) (FW) (FX) (FY) (FZ) (GA) (GB) (GC) (GD) (GE) (GF) (GG) (GH) (GI) (GJ) (GK) (GL) (GM) (GN) (GO) (GP) (GQ) (GR) (GS) (GT) (GU) (GV) (GW) (GX) (GY) (GZ) (HA) (HB) (HC) (HD) (HE) (HF) (HG) (HH) (HI) (HJ) (HK) (HL) (HM) (HN) (HO) (HP) (HQ) (HR) (HS) (HT) (HU) (HV) (HW) (HX) (HY) (HZ) (IA) (IB) (IC) (ID) (IE) (IF) (IG) (IH) (II) (IJ) (IK) (IL) (IM) (IN) (IO) (IP) (IQ) (IR) (IS) (IT) (IU) (IV) (IW) (IX) (IY) (IZ) (JA) (JB) (JC) (JD) (JE) (JF) (JG) (JH) (JI) (JJ) (JK) (JL) (JM) (JN) (JO) (JP) (JQ) (JR) (JS) (JT) (JU) (JV) (JW) (JX) (JY) (JZ) (KA) (KB) (KC) (KD) (KE) (KF) (KG) (KH) (KI) (KJ) (KK) (KL) (KM) (KN) (KO) (KP) (KQ) (KR) (KS) (KT) (KU) (KV) (KW) (KX) (KY) (KZ) (LA) (LB) (LC) (LD) (LE) (LF) (LG) (LH) (LI) (LJ) (LK) (LL) (LM) (LN) (LO) (LP) (LQ) (LR) (LS) (LT) (LU) (LV) (LW) (LX) (LY) (LZ) (MA) (MB) (MC) (MD) (ME) (MF) (MG) (MH) (MI) (MJ) (MK) (ML) (MM) (MN) (MO) (MP) (MQ) (MR) (MS) (MT) (MU) (MV) (MW) (MX) (MY) (MZ) (NA) (NB) (NC) (ND) (NE) (NF) (NG) (NH) (NI) (NJ) (NK) (NL) (NM) (NN) (NO) (NP) (NQ) (NR) (NS) (NT) (NU) (NV) (NW) (NX) (NY) (NZ) (OA) (OB) (OC) (OD) (OE) (OF) (OG) (OH) (OI) (OJ) (OK) (OL) (OM) (ON) (OO) (OP) (OQ) (OR) (OS) (OT) (OU) (OV) (OW) (OX) (OY) (OZ) (PA) (PB) (PC) (PD) (PE) (PF) (PG) (PH) (PI) (PJ) (PK) (PL) (PM) (PN) (PO) (PP) (PQ) (PR) (PS) (PT) (PU) (PV) (PW) (PX) (PY) (PZ) (QA) (QB) (QC) (QD) (QE) (QF) (QG) (QH) (QI) (QJ) (QK) (QL) (QM) (QN) (QO) (QP) (QQ) (QR) (QS) (QT) (QU) (QV) (QW) (QX) (QY) (QZ) (RA) (RB) (RC) (RD) (RE) (RF) (RG) (RH) (RI) (RJ) (RK) (RL) (RM) (RN) (RO) (RP) (RQ) (RR) (RS) (RT) (RU) (RV) (RW) (RX) (RY) (RZ) (SA) (SB) (SC) (SD) (SE) (SF) (SG) (SH) (SI) (SJ) (SK) (SL) (SM) (SN) (SO) (SP) (SQ) (SR) (SS) (ST) (SU) (SV) (SW) (SX) (SY) (SZ) (TA) (TB) (TC) (TD) (TE) (TF) (TG) (TH) (TI) (TJ) (TK) (TL) (TM) (TN) (TO) (TP) (TQ) (TR) (TS) (TT) (TU) (TV) (TW) (TX) (TY) (TZ) (UA) (UB) (UC) (UD) (UE) (UF) (UG) (UH) (UI) (UJ) (UK) (UL) (UM) (UN) (UO) (UP) (UQ) (UR) (US) (UT) (UU) (UV) (UW) (UX) (UY) (UZ) (VA) (VB) (VC) (VD) (VE) (VF) (VG) (VH) (VI) (VJ) (VK) (VL) (VM) (VN) (VO) (VP) (VQ) (VR) (VS) (VT) (VU) (VV) (VW) (VX) (VY) (VZ) (WA) (WB) (WC) (WD) (WE) (WF) (WG) (WH) (WI) (WJ) (WK) (WL) (WM) (WN) (WO) (WP) (WQ) (WR) (WS) (WT) (WU) (WV) (WW) (WX) (WY) (WZ) (XA) (XB) (XC) (XD) (XE) (XF) (XG) (XH) (XI) (XJ) (XK) (XL) (XM) (XN) (XO) (XP) (XQ) (XR) (XS) (XT) (XU) (XV) (XW) (XX) (XY) (XZ) (YA) (YB) (YC) (YD) (YE) (YF) (YG) (YH) (YI) (YJ) (YK) (YL) (YM) (YN) (YO) (YP) (YQ) (YR) (YS) (YT) (YU) (YV) (YW) (YX) (YZ) (ZA) (ZB) (ZC) (ZD) (ZE) (ZF) (ZG) (ZH) (ZI) (ZJ) (ZK) (ZL) (ZM) (ZN) (ZO) (ZP) (ZQ) (ZR) (ZS) (ZT) (ZU) (ZV) (ZW) (ZX) (ZY) (ZZ) (AA) (AB) (AC) (AD) (AE) (AF) (AG) (AH) (AI) (AJ) (AK) (AL) (AM) (AN) (AO) (AP) (AQ) (AR) (AS) (AT) (AU) (AV) (AW) (AX) (AY) (AZ) (BA) (BB) (BC) (BD) (BE) (BF) (BG) (BH) (BI) (BJ) (BK) (BL) (BM) (BN) (BO) (BP) (BQ) (BR) (BS) (BT) (BU) (BV) (BW) (BX) (BY) (BZ) (CA) (CB) (CC) (CD) (CE) (CF) (CG) (CH) (CI) (CJ) (CK) (CL) (CM) (CN) (CO) (CP) (CQ) (CR) (CS) (CT) (CU) (CV) (CW) (CX) (CY) (CZ) (DA) (DB) (DC) (DD) (DE) (DF) (DG) (DH) (DI) (DJ) (DK) (DL) (DM) (DN) (DO) (DP) (DQ) (DR) (DS) (DT) (DU) (DV) (DW) (DX) (DY) (DZ) (EA) (EB) (EC) (ED) (EE) (EF) (EG) (EH) (EI) (EJ) (EK) (EL) (EM) (EN) (EO) (EP) (EQ) (ER) (ES) (ET) (EU) (EV) (EW) (EX) (EY) (EZ) (FA) (FB) (FC) (FD) (FE) (FF) (FG) (FH) (FI) (FJ) (FK) (FL) (FM) (FN) (FO) (FP) (FQ) (FR) (FS) (FT) (FU) (FV) (FW) (FX) (FY) (FZ) (GA) (GB) (GC) (GD) (GE) (GF) (GG) (GH) (GI) (GJ) (GK) (GL) (GM) (GN) (GO) (GP) (GQ) (GR) (GS) (GT) (GU) (GV) (GW) (GX) (GY) (GZ) (HA) (HB) (HC) (HD) (HE) (HF) (HG) (HH) (HI) (HJ) (HK) (HL) (HM) (HN) (HO) (HP) (HQ) (HR) (HS) (HT) (HU) (HV) (HW) (HX) (HY) (HZ) (IA) (IB) (IC) (ID) (IE) (IF) (IG) (IH) (II) (IJ) (IK) (IL) (IM) (IN) (IO) (IP) (IQ) (IR) (IS) (IT) (IU) (IV) (IW) (IX) (IY) (IZ) (JA) (JB) (JC) (JD) (JE) (JF) (JG) (JH) (JI) (JJ) (JK) (JL) (JM) (JN) (JO) (JP) (JQ) (JR) (JS) (JT) (JU) (JV) (JW) (JX) (JY) (JZ) (KA) (KB) (KC) (KD) (KE) (KF) (KG) (KH) (KI) (KJ) (KK) (KL) (KM) (KN) (KO) (KP) (KQ) (KR) (KS) (KT) (KU) (KV) (KW) (KX) (KY) (KZ) (LA) (LB) (LC) (LD) (LE) (LF) (LG) (LH) (LI) (LJ) (LK) (LL) (LM) (LN) (LO) (LP) (LQ) (LR) (LS) (LT) (LU) (LV) (LW) (LX) (LY) (LZ) (MA) (MB) (MC) (MD) (ME) (MF) (MG) (MH) (MI) (MJ) (MK) (ML) (MM) (MN) (MO) (MP) (MQ) (MR) (MS) (MT) (MU) (MV) (MW) (MX) (MY) (MZ) (NA) (NB) (NC) (ND) (NE) (NF) (NG) (NH) (NI) (NJ) (NK) (NL) (NM) (NN) (NO) (NP) (NQ) (NR) (NS) (NT) (NU) (NV) (NW) (NX) (NY) (NZ) (OA) (OB) (OC) (OD) (OE) (OF) (OG) (OH) (OI) (OJ) (OK) (OL) (OM) (ON) (OO) (OP) (OQ) (OR) (OS) (OT) (OU) (OV) (OW) (OX) (OY) (OZ) (PA) (PB) (PC) (PD) (PE) (PF) (PG) (PH) (PI) (PJ) (PK) (PL) (PM) (PN) (PO) (PP) (PQ) (PR) (PS) (PT) (PU) (PV) (PW) (PX) (PY) (PZ) (QA) (QB) (QC) (QD) (QE) (QF) (QG) (QH) (QI) (QJ) (QK) (QL) (QM) (QN) (QO) (QP) (QQ) (QR) (QS) (QT) (QU) (QV) (QW) (QX) (QY) (QZ) (RA) (RB) (RC) (RD) (RE) (RF) (RG) (RH) (RI) (RJ) (RK) (RL) (RM) (RN) (RO) (RP) (RQ) (RR) (RS) (RT) (RU) (RV) (RW) (RX) (RY) (RZ) (SA) (SB) (SC) (SD) (SE) (SF) (SG) (SH) (SI) (SJ) (SK) (SL) (SM) (SN) (SO) (SP) (SQ) (SR) (SS) (ST) (SU) (SV) (SW) (SX) (SY) (SZ) (TA) (TB) (TC) (TD) (TE) (TF) (TG) (TH) (TI) (TJ) (TK) (TL) (TM) (TN) (TO) (TP) (TQ) (TR) (TS) (TT) (TU) (TV) (TW) (TX) (TY) (TZ) (UA) (UB) (UC) (UD) (UE) (UF) (UG) (UH) (UI) (UJ) (UK) (UL) (UM) (UN) (UO) (UP) (UQ) (UR) (US) (UT) (UU) (UV) (UW) (UX) (UY) (UZ) (VA) (VB) (VC) (VD) (VE) (VF) (VG) (VH) (VI) (VJ) (VK) (VL) (VM) (VN) (VO) (VP) (VQ) (VR) (VS) (VT) (VU) (VV) (VW) (VX) (VY) (VZ) (WA) (WB) (WC) (WD) (WE) (WF) (WG) (WH) (WI) (WJ) (WK) (WL) (WM) (WN) (WO) (WP) (WQ) (WR) (WS) (WT) (WU) (WV) (WW) (WX) (WY) (WZ) (XA) (XB) (XC) (XD) (XE) (XF) (XG) (XH) (XI) (XJ) (XK) (XL) (XM) (XN) (XO) (XP) (XQ) (XR) (XS) (XT) (XU) (XV) (XW) (XX) (XY) (XZ) (YA) (YB) (YC) (YD) (YE) (YF) (YG) (YH) (YI) (YJ) (YK) (YL) (YM) (YN) (YO) (YP) (YQ) (YR) (YS) (YT) (YU) (YV) (YW) (YX) (YZ) (ZA) (ZB) (ZC) (ZD) (ZE) (ZF) (ZG) (ZH) (ZI) (ZJ) (ZK) (ZL) (ZM) (ZN) (ZO) (ZP) (ZQ) (ZR) (ZS) (ZT) (ZU) (ZV) (ZW) (ZX) (ZY) (ZZ)

() B

For the six months ended
June 30,
2020 2019
(Unaudited) ()

(B)	36,409,947	52,064,124
	72,769,749	73,040,000
B (B)	0.50	0.71

() F 13, 2018, C 2,460,000 D
A D
k , A B
E 7, 2,460,000 D
C 30, 2020.

F 30, 2020, C
899,700 k ,
k C

() D

D
C F
30, 2020,
B36,409,947. 73,034,363. B0.50.
F 30, 2019,
B52,064,124. 73,915,743.
B0.70.

11.3.5 Income Tax Expense

[illegible]

For the six months ended
June 30,
2020 2019
(Unaudited) (Unaudited)

C	23,778,834	14,824,769
D	(13,276,086)	(7,704,851)
	<u>10,502,748</u>	<u>7,119,918</u>

For the six months ended
June 30,
2020 2019
(Unaudited) (Unaudited)

	39,403,983	52,661,149
25%	9,850,996	13,165,287
C	579,650	1,158,271
F	121,674	119,184
A	(490,212)	(431,227)
	—	(318,561)
D	440,640	51,944
	—	(6,624,980)
	10,502,748	7,119,918

11.3.6 Dividends

30, 2020, B 0 1 7

12 DEFINITIONS

A. C. — B.

B. , C. . (北京怡寧醫院有限公司),
A. 17, 2015, C. ,

B. — C.

C. , C. . (蒼南康寧醫院有限公司),
15, 2012, C. , -

C. , C. . (長春康林心理醫院有限公司),
C. F. 16, 2016, C. , -

C. , C. . k
k E (k C : 2120)

C. C. — C. A. 14

D. () — () C.

D. () — () C. ,
B1.00 , B
k

, C. . (溫州怡寧老年醫院有限公司),
2, 2015, C. ,

C.

() — ()
B1.00 , B
k E

本公司、D、A、C

E、k

k E、k E

C、(淮南康寧醫院有限公司), C
22, 2017, C

C、(廊坊怡寧醫院有限公司), k
C、(廊坊市怡寧醫院管理有限公司)), C
D 2, 2015, C
A, 2, 2020

C、C、(台州市路橋慈寧醫院有限公司), k
C、(台州市路橋怡寧醫院有限公司)), C
D 12, 2016, C

A、C

C、C、
C、
C、(青田康寧醫院有限公司), C
A 1, 2011, C

C、(衢州怡寧醫院有限公司), C
20, 2015, C

30, 2020

